---
title: "Splash Beverage reports ~64% reduction in loss from continuing operations for H1 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296497955.md"
description: "Splash Beverage reported a ~64% reduction in loss from continuing operations for H1 2026, dropping to ~$4 million from $11 million year-over-year. This improvement stems from cost-reduction initiatives as the company transitions toward cannabinoid-based pharmaceutical and veterinary opportunities under the new name Endovia Health Sciences. Key developments include an exclusive global license for CannEpil®, a collaboration with Lupvindol Biosciences for veterinary product development, and preparations to relaunch CannEpil® in UK, Ireland, and Latin American markets."
datetime: "2026-08-20T13:13:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296497955.md)
  - [en](https://longbridge.com/en/news/296497955.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296497955.md)
generator: "portal-rs"
---

# Splash Beverage reports ~64% reduction in loss from continuing operations for H1 2026

Splash Beverage reported a roughly 64% decline in loss from continuing operations for the six months ended June 30, 2026, driven by cost-reduction initiatives as the company transitions its business. Management cites the improvement from approximately $11 million to approximately $4 million year‑over‑year for the six-month period and is repositioning the company toward cannabinoid-based pharmaceutical and veterinary opportunities. The company announced post‑quarter licensing and collaboration agreements supporting the strategic shift and a planned rebrand to Endovia Health Sciences effective August 24, 2026.

**Financial Highlights**

-   Loss from continuing operations for the six months ended June 30, 2026: approximately $4 million (versus approximately $11 million for the six months ended June 30, 2025).
-   Improvement in loss from continuing operations year‑over‑year for the six‑month period: approximately $7 million (approximately 64% improvement).
-   Company attributes improvement primarily to significant cost-reduction initiatives implemented over the past six months.
-   No specific figures provided in the filing for revenue, gross profit, operating income, net income, or adjusted diluted EPS; those metrics are not reported in the press release.

**Business Highlights**

-   Strategic transformation toward cannabinoid-based health sciences, focusing on pharmaceutical, veterinary and consumer wellness opportunities under the Endovia Health Sciences identity.
-   Entered an exclusive global license for CannEpil®, a pharmaceutical-grade cannabinoid platform originally developed for drug-resistant epilepsy, providing a foundational pharmaceutical asset.
-   Expanded the CannEpil® license to include veterinary applications, initially targeting companion-animal oncology and chronic pain management.
-   Executed a development and collaboration agreement with Lupvindol Biosciences Ltd. for Lupvindol to lead scientific and FDA regulatory development of a CannEpil-based veterinary product through the FDA Center for Veterinary Medicine INAD and Conditional Approval pathways.
-   Initiated preparations to relaunch CannEpil® through existing commercial and distribution relationships in the United Kingdom, Ireland and select Latin American markets.
-   Implemented significant corporate overhead and administrative cost reductions and simplified the company’s operating structure and legacy obligations to create a more efficient platform for the announced strategic initiatives.

Original SEC Filing: SPLASH BEVERAGE GROUP, INC. \[ SBEV \] - 8-K - Aug. 20, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SBEV.US](https://longbridge.com/en/quote/SBEV.US.md)
- [EDVA.US](https://longbridge.com/en/quote/EDVA.US.md)
- [SBEV+.US](https://longbridge.com/en/quote/SBEV+.US.md)
- [SBEVW.US](https://longbridge.com/en/quote/SBEVW.US.md)

## Related News & Research

- [Splash Beverage expands CannEpil license to veterinary therapeutics in 8-K amendment](https://longbridge.com/en/news/294409288.md)
- [Splash Beverage finalizes joint venture with cannabinoid pharma group for CannEpil veterinary program](https://longbridge.com/en/news/294208182.md)
- [Should Chewy’s Vet Clinic Push and Autoship Dependence Reshape Long-Term Cash Flows for CHWY Investors?](https://longbridge.com/en/news/297366123.md)
- [Alfresa unit signs commercialization deal for next-gen veterinary healthcare platform](https://longbridge.com/en/news/297593627.md)
- [16:22 ETAirvet and HABRI Partner to Advance the Human-Animal Bond](https://longbridge.com/en/news/297558124.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**